Literature DB >> 26349984

MicroRNA-induced drug resistance in gastric cancer.

Rashedeh Dehghanzadeh1, Farhad Jadidi-Niaragh2, Tohid Gharibi1, Mehdi Yousefi3.   

Abstract

Drug resistance remains one of the major reasons of therapy failure in gastric cancer patients. Although the mechanisms of anticancer drug resistance have been broadly investigated, they have not been completely understood. Accumulating reports have recently highlighted the involvement of endogenous non-coding RNAs, known as microRNAs, in the evolution of cancer cell drug resistance. MiRNAs have been characterized as major regulators of crucial genes implicated in the chemoresistance phenotype of gastric cancer cells. MiRNA-based therapy in the future may provide a new strategy to overcome drug resistance. This review summarizes the current knowledge on the role of miRNAs in regulating drug resistance in gastric cancer and their potential to develop targeted therapies and personalized treatment for managing drug resistant gastric cancers.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Drug resistance; Gastric cancer; microRNA

Mesh:

Substances:

Year:  2015        PMID: 26349984     DOI: 10.1016/j.biopha.2015.08.009

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  23 in total

1.  Overexpression of microRNA-15 increases the chemosensitivity of colon cancer cells to 5-fluorouracil and oxaliplatin by inhibiting the nuclear factor-κB signalling pathway and inducing apoptosis.

Authors:  Lili Liu; Dan Wang; Ying Qiu; Hongyan Dong; Xuemei Zhan
Journal:  Exp Ther Med       Date:  2017-12-22       Impact factor: 2.447

2.  RP11-874J12.4, a novel lncRNA, confers chemoresistance in human gastric cancer cells by sponging miR-3972 and upregulating SSR2 expression.

Authors:  Yi Liu; Jian Cao; Yan-Song Pu; Yu Ma; Min Wu; Jian-Hua Wang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  MicroRNA-25 contributes to cisplatin resistance in gastric cancer cells by inhibiting forkhead box O3a.

Authors:  Jingbo He; Huixiong Qi; Fang Chen; Chuanhua Cao
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

4.  LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.

Authors:  Yongxian Cao; Feng Zhang; Haotian Wang; Chunhua Bi; Jinpeng Cui; Fenghai Liu; Huazheng Pan
Journal:  Mol Cell Biochem       Date:  2020-09-23       Impact factor: 3.396

5.  MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.

Authors:  Hannah L Moody; Michael J Lind; Stephen G Maher
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-08       Impact factor: 8.886

6.  Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.

Authors:  Peiming Zheng; Lei Chen; Xiangliang Yuan; Qin Luo; Yi Liu; Guohua Xie; Yanhui Ma; Lisong Shen
Journal:  J Exp Clin Cancer Res       Date:  2017-04-13

7.  MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.

Authors:  Ke-Ting Que; Yun Zhou; Yu You; Zhen Zhang; Xiao-Ping Zhao; Jian-Ping Gong; Zuo-Jin Liu
Journal:  J Exp Clin Cancer Res       Date:  2018-11-06

8.  MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.

Authors:  Bo-Chuan Lin; Dong Huang; Chao-Qun Yu; Yong Mou; Yuan-Hang Liu; Da-Wei Zhang; Feng-Jun Shi
Journal:  Med Sci Monit       Date:  2016-05-25

9.  Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis.

Authors:  Li-Dong Zu; Xing-Chun Peng; Zhi Zeng; Jing-Long Wang; Li-Li Meng; Wei-Wei Shen; Chun-Ting Hu; Ye Yang; Guo-Hui Fu
Journal:  J Exp Clin Cancer Res       Date:  2018-06-04

10.  LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis.

Authors:  Yanjie Liu; Ruixia Guo; Yuhuan Qiao; Liping Han; Mingzhu Liu
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.